Literature DB >> 11796594

Mycoplasma pneumoniae induces chronic respiratory infection, airway hyperreactivity, and pulmonary inflammation: a murine model of infection-associated chronic reactive airway disease.

Robert D Hardy1, Hasan S Jafri, Kurt Olsen, Jeanine Hatfield, Janie Iglehart, Beverly B Rogers, Padma Patel, Gail Cassell, George H McCracken, Octavio Ramilo.   

Abstract

Because chronic Mycoplasma pneumoniae respiratory infection is hypothesized to play a role in asthma, the potential of M. pneumoniae to establish chronic respiratory infection with associated pulmonary disease was investigated in a murine model. BALB/c mice were intranasally inoculated once with M. pneumoniae and examined at 109, 150, 245, 368, and 530 days postinoculation. M. pneumoniae was detected in bronchoalveolar lavage fluid by culture or PCR in 70 and 22% of mice at 109 and 530 days postinoculation, respectively. Lung histopathology was normal up to 368 days postinoculation. At 530 days, however, 78% of the mice inoculated with M. pneumoniae demonstrated abnormal histopathology characterized by peribronchial and perivascular mononuclear infiltrates. A mean histopathologic score (HPS) at 530 days of 5.1 was significantly greater (P < 0.01) than that for controls (HPS score of 0). Serum anti-M. pneumoniae immunoglobulin G was detectable in all of the mice inoculated with M. pneumoniae and was inversely correlated with HPS (r = -0.95, P = 0.01) at 530 days postinoculation. Unrestrained whole-body plethysmography measurement of enhanced pause revealed significantly elevated airway methacholine reactivity in M. pneumoniae-inoculated mice compared with that in controls at 245 days (P = 0.03) and increased airway obstruction at 530 days (P = 0.01). Murine M. pneumoniae respiratory infection can lead to chronic pulmonary disease characterized by airway hyperreactivity, airway obstruction, and histologic inflammation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11796594      PMCID: PMC127700          DOI: 10.1128/IAI.70.2.649-654.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  19 in total

1.  Respiratory syncytial virus infection results in airway hyperresponsiveness and enhanced airway sensitization to allergen.

Authors:  J Schwarze; E Hamelmann; K L Bradley; K Takeda; E W Gelfand
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

2.  Respiratory syncytial virus affects pulmonary function in BALB/c mice.

Authors:  S M van Schaik; G Enhorning; I Vargas; R C Welliver
Journal:  J Infect Dis       Date:  1998-02       Impact factor: 5.226

3.  Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography.

Authors:  E Hamelmann; J Schwarze; K Takeda; A Oshiba; G L Larsen; C G Irvin; E W Gelfand
Journal:  Am J Respir Crit Care Med       Date:  1997-09       Impact factor: 21.405

4.  Avoiding false positives with PCR.

Authors:  S Kwok; R Higuchi
Journal:  Nature       Date:  1989-05-18       Impact factor: 49.962

Review 5.  Mycoplasma pneumoniae disease: clinical spectrum, pathophysiology, epidemiology, and control.

Authors:  F W Denny; W A Clyde; W P Glezen
Journal:  J Infect Dis       Date:  1971-01       Impact factor: 5.226

6.  Detection of Mycoplasma pneumoniae in the airways of adults with chronic asthma.

Authors:  M Kraft; G H Cassell; J E Henson; H Watson; J Williamson; B P Marmion; C A Gaydos; R J Martin
Journal:  Am J Respir Crit Care Med       Date:  1998-09       Impact factor: 21.405

7.  Infection-induced airway fibrosis in two rat strains with differential susceptibility.

Authors:  J C McIntosh; J W Simecka; S E Ross; J K Davis; E J Miller; G H Cassell
Journal:  Infect Immun       Date:  1992-07       Impact factor: 3.441

8.  Experimental Mycoplasma pulmonis infection in pathogen-free mice. Models for studying mycoplasmosis of the respiratory tract.

Authors:  J R Lindsey; H Cassell
Journal:  Am J Pathol       Date:  1973-07       Impact factor: 4.307

9.  Laboratory diagnosis of Mycoplasma pneumoniae infection. 4. Antigen capture and PCR-gene amplification for detection of the Mycoplasma: problems of clinical correlation.

Authors:  J Williamson; B P Marmion; D A Worswick; T W Kok; G Tannock; R Herd; R J Harris
Journal:  Epidemiol Infect       Date:  1992-12       Impact factor: 2.451

10.  The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airway hyperresponsiveness.

Authors:  J A Gonzalo; C M Lloyd; D Wen; J P Albar; T N Wells; A Proudfoot; C Martinez-A; M Dorf; T Bjerke; A J Coyle; J C Gutierrez-Ramos
Journal:  J Exp Med       Date:  1998-07-06       Impact factor: 14.307

View more
  35 in total

1.  SPLUNC1 promotes lung innate defense against Mycoplasma pneumoniae infection in mice.

Authors:  Fabienne Gally; Y Peter Di; Sean K Smith; Maisha N Minor; Yang Liu; Donna L Bratton; S Courtney Frasch; Nicole M Michels; Stephanie R Case; Hong Wei Chu
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

2.  Synthesis and distribution of CARDS toxin during Mycoplasma pneumoniae infection in a murine model.

Authors:  T R Kannan; Jacqueline J Coalson; Marianna Cagle; Oxana Musatovova; R Doug Hardy; Joel B Baseman
Journal:  J Infect Dis       Date:  2011-09-28       Impact factor: 5.226

3.  Mycoplasma pneumoniae CARDS toxin induces pulmonary eosinophilic and lymphocytic inflammation.

Authors:  Jorge L Medina; Jacqueline J Coalson; Edward G Brooks; Vicki T Winter; Adriana Chaparro; Molly F R Principe; Thirumalai R Kannan; Joel B Baseman; Peter H Dube
Journal:  Am J Respir Cell Mol Biol       Date:  2012-01-26       Impact factor: 6.914

Review 4.  Mycoplasma pneumoniae from the Respiratory Tract and Beyond.

Authors:  Ken B Waites; Li Xiao; Yang Liu; Mitchell F Balish; T Prescott Atkinson
Journal:  Clin Microbiol Rev       Date:  2017-07       Impact factor: 26.132

5.  Evaluation of LBM415 (NVP PDF-713), a novel peptide deformylase inhibitor, for treatment of experimental Mycoplasma pneumoniae pneumonia.

Authors:  Monica Fonseca-Aten; Christine M Salvatore; Asunción Mejías; Ana M Ríos; Susana Chávez-Bueno; Kathy Katz; Ana M Gómez; George H McCracken; R Doug Hardy
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

Review 6.  Mycoplasma pneumoniae and its role as a human pathogen.

Authors:  Ken B Waites; Deborah F Talkington
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

7.  Atypical bacteria and macrolides in asthma.

Authors:  Paraskevi Xepapadaki; Ioanna Koutsoumpari; Vasiliki Papaevagelou; Christina Karagianni; Nikolaos G Papadopoulos
Journal:  Allergy Asthma Clin Immunol       Date:  2008-09-15       Impact factor: 3.406

8.  Mycoplasma pneumoniae Community Acquired Respiratory Distress Syndrome toxin expression reveals growth phase and infection-dependent regulation.

Authors:  T R Kannan; Oxana Musatovova; Sowmya Balasubramanian; Marianna Cagle; Jarrat L Jordan; Thomas M Krunkosky; Alan Davis; Robert D Hardy; Joel B Baseman
Journal:  Mol Microbiol       Date:  2010-02-28       Impact factor: 3.501

9.  Impact of cethromycin (ABT-773) therapy on microbiological, histologic, immunologic, and respiratory indices in a murine model of Mycoplasma pneumoniae lower respiratory infection.

Authors:  Ana María Ríos; Asunción Mejías; Susana Chávez-Bueno; Mónica Fonseca-Aten; Kathy Katz; Jeanine Hatfield; Ana María Gómez; Hasan S Jafri; George H McCracken; Octavio Ramilo; Robert Doug Hardy
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

10.  Analysis of pulmonary inflammation and function in the mouse and baboon after exposure to Mycoplasma pneumoniae CARDS toxin.

Authors:  R Doug Hardy; Jacqueline J Coalson; Jay Peters; Adriana Chaparro; Chonnamet Techasaensiri; Angelene M Cantwell; T R Kannan; Joel B Baseman; Peter H Dube
Journal:  PLoS One       Date:  2009-10-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.